Accelerating progress to innovation for patients: Trial design and risk stratification

Area of Science:

• Oncology
• Clinical Trial Design
• Breast Cancer Research

Background:

• Historically, early breast cancer trials enrolled broad patient populations.
• Current trials increasingly focus on specific risk groups (low-to-intermediate or intermediate-to-high risk) for targeted therapies.
• Subtype and risk stratification are crucial for defining appropriate patient populations in clinical trials.

Purpose of the Study:

• To analyze the evolution of early breast cancer trial design.
• To highlight the integration of risk stratification and patient subtypes in modern trials.
• To identify opportunities for improving future clinical trial designs and accelerating therapeutic innovation.

Main Methods:

• Review of recent clinical trial enrollment strategies in early breast cancer.
• Analysis of how risk stratification and patient subtypes are used to define trial populations.
• Examination of therapeutic strategies for specific breast cancer subtypes (e.g., triple-negative, hormone receptor-positive/HER2-negative).

Main Results:

• Trials are shifting from 'all-comers' to precisely defined populations based on risk and subtype.
• Residual disease after neoadjuvant therapy is a key stratification factor for triple-negative breast cancer trials.
• Trials for hormone receptor-positive, HER2-negative breast cancer are investigating adjuvant CDK4/6 inhibitors in intermediate-to-high risk groups, yielding heterogeneous results.

Conclusions:

• Recent clinical trial results offer valuable insights for refining future trial designs.
• Integrating risk stratification and subtype-specific approaches enhances the precision of early breast cancer trials.
• Improved trial design is essential for accelerating therapeutic advancements in early breast cancer.